Selenium for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: Se, Selenomethionine, Sodium Selenite, Selenium Yeast, Methylselenocysteine, Selenocysteine

Motivation

Selenium is an essential trace mineral that the body cannot manufacture and must obtain from the diet. It acts almost exclusively through its incorporation into selenoproteins, which underpin antioxidant defense. Soil concentration determines how much reaches the food supply, so intake varies several-fold between regions, and dietary exposure differs sharply across countries.

Once a niche concern of agricultural science, selenium drew broad clinical interest after early trials raised the possibility of benefits on cancer and other chronic-disease outcomes. Some researchers describe the relationship between selenium status and health outcomes as U-shaped, where both inadequate and excessive exposure may shift outcomes; others read the same data differently and continue to debate whether status, dose, or chemical form is the primary driver of effects. The breadth of these competing readings sets selenium apart from most micronutrients and is examined throughout this review.

This evidence review examines what is and is not supported by current research on selenium for general health and longevity, framing benefits, risks, and protocol considerations for adults who already manage their nutrition and supplementation, and who weigh interventions in light of their own baseline status rather than population averages.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Selenium

Provides an encyclopedic overview of selenium as a chemical element, including its physical and chemical properties, biological roles, dietary sources, and significance in human health and disease.

Examine

Selenium benefits, dosage, and side effects

Offers a detailed, evidence-graded breakdown of selenium’s effects, dosage guidance, side effects, and the underlying research for use in immunity, thyroid function, cardiovascular health, and metabolic outcomes.

ConsumerLab

Selenium Supplement Reviews & Top Pick

Independently tests selenium supplements for label accuracy and contamination, compares cost per dose across products, and identifies top picks for highly absorbable forms among widely available brands.

Systematic Reviews

A selection of high-quality systematic reviews and meta-analyses examining selenium supplementation across cancer, thyroid autoimmunity, immune function, metabolic risk, and lipid outcomes.

Selenium for preventing cancer - Vinceti et al., 2018

A Cochrane review of 10 RCTs (randomized controlled trials) involving 27,232 participants, finding no overall reduction in cancer risk with selenium supplementation and signaling concern about increased high-grade prostate cancer and type 2 diabetes risk in selenium-replete populations.
Selenium Supplementation in Patients with Hashimoto Thyroiditis - Huwiler et al., 2024

A meta-analysis of 35 RCTs reporting that selenium supplementation reduced TSH (thyroid-stimulating hormone, the pituitary signal that drives thyroid output) in untreated patients and lowered TPOAb (thyroid peroxidase antibodies, markers of autoimmune thyroid attack) across all patients, with safety comparable to placebo.
Selenium and immune function: a systematic review and meta-analysis of experimental human studies - Filippini et al., 2023

A meta-analysis of 9 trials finding inconsistent effects on most immune markers but a clear increase in NK (natural killer, immune cells that destroy infected or cancerous cells) cell lytic activity, with an inverted U-shaped pattern for NK cell count by selenium status.
Selenium exposure and the risk of type 2 diabetes - Vinceti et al., 2018

A meta-analysis of 50 observational studies and 5 RCTs reporting an 11% increase in type 2 diabetes risk with selenium supplementation and a clear dose-response in observational data.
Effect of Selenium Supplementation on Lipid Profile - Hasani et al., 2018

A meta-analysis of 11 RCTs in 1,221 participants reporting modest reductions in total cholesterol, triglycerides, and VLDL (very low-density lipoprotein, a triglyceride-rich cholesterol particle) with selenium supplementation, without significant change in LDL (low-density lipoprotein, the “bad” cholesterol particle that delivers cholesterol to tissues) or HDL (high-density lipoprotein, the “good” cholesterol particle that returns cholesterol to the liver).

Mechanism of Action

Selenium acts almost exclusively through its incorporation into selenoproteins, a family of about 25 proteins in humans that contain the amino acid selenocysteine at their catalytic site. The selenol group on selenocysteine is more easily ionized than the sulfur-based thiol group on cysteine, which allows selenoproteins to perform redox reactions that ordinary cysteine-based enzymes cannot.

The principal selenoprotein families relevant to health are:

Glutathione peroxidases (GPx, glutathione peroxidase, an enzyme that neutralizes hydrogen peroxide and lipid peroxides): Reduce hydrogen peroxide and lipid hydroperoxides to water and alcohols, using glutathione as the electron donor; protect cell membranes and DNA from oxidative damage.
Thioredoxin reductases (TrxR, thioredoxin reductase, an enzyme that maintains cellular redox balance): Recycle thioredoxin, supporting DNA synthesis, redox signaling, and protection against oxidative stress.
Iodothyronine deiodinases (DIO, iodothyronine deiodinase, an enzyme that activates and inactivates thyroid hormone): Convert thyroxine (T4) to the active triiodothyronine (T3) and clear excess hormone, making selenium central to thyroid hormone metabolism.
Selenoprotein P (SELENOP, selenoprotein P, the main selenium transport protein in plasma): Distributes selenium from the liver to peripheral tissues, including brain and testes, and contributes to extracellular antioxidant capacity.

Mechanistic claims for selenium’s benefit beyond enzyme support, including direct anti-cancer effects of methylselenocysteine and selenodiglutathione, exist but are largely based on cell-culture and animal data; the competing view, supported by large RCTs in selenium-replete men, is that supraphysiological intake produces no additional benefit and may shift selenium compounds from antioxidant to pro-oxidant behavior. Both perspectives are reflected in the body of randomized evidence and remain unresolved.

As a nutrient rather than a pharmacological agent, selenium does not have a conventional half-life, selectivity, or CYP-based metabolism profile in the manner of a drug, but key kinetic properties are noted in the Therapeutic Protocol section.

Historical Context & Evolution

Selenium was identified in 1817 by the Swedish chemist Jons Jacob Berzelius and was regarded for more than a century primarily as a livestock toxin in regions with selenium-rich soils. Outbreaks of “alkali disease” (a chronic selenium poisoning of livestock causing hair loss and lameness) in cattle and horses in parts of the United States in the early twentieth century reinforced this view.

The reversal began in 1957, when Schwarz and Foltz showed that trace amounts of selenium prevented liver necrosis in vitamin-E-deficient rats, establishing selenium as a nutritional essential. In the 1970s, the discovery of Keshan disease (a juvenile cardiomyopathy, a disease of the heart muscle) in low-selenium regions of China, and its prevention by selenium supplementation, firmly established the role of selenium in human nutrition. The biochemical basis became clearer with the identification of glutathione peroxidase as a selenoenzyme in the 1970s and the gradual mapping of the broader selenoprotein family in the decades that followed.

Interest in selenium for chronic disease prevention accelerated after the 1996 Nutritional Prevention of Cancer (NPC) trial reported a roughly 50% reduction in cancer mortality with 200 micrograms per day of selenium-enriched yeast in adults with prior nonmelanoma skin cancer. The much larger SELECT (Selenium and Vitamin E Cancer Prevention Trial), conducted in selenium-replete North American men, did not replicate any cancer prevention benefit and instead reported increased risk of high-grade prostate cancer and type 2 diabetes in selenium-supplemented arms. This sequence is often described as the field moving from enthusiasm to caution. Both lines of evidence remain in the literature. Some readings of the apparent contradiction attribute it to baseline status, with deficient populations more likely to benefit and replete populations more likely to be harmed; other readings point to differences in selenium chemical form, supplementation duration, or trial population characteristics, and some reviewers maintain that SELECT effectively challenged the cancer-prevention case across populations. The 2009 Cochrane analysis and its updates have framed the question in a status-dependent way, while later commentary has continued to contest whether status alone explains the divergence.

Expected Benefits

High 🟩 🟩 🟩

Thyroid Autoimmunity Support

In Hashimoto thyroiditis (an autoimmune disorder in which immune cells attack the thyroid), selenium supplementation reduces thyroid antibodies and modestly improves TSH in untreated patients. A 2024 meta-analysis of 35 RCTs found a reduction in TPOAb of about one standardized standard deviation versus placebo, with adverse event rates similar to placebo. The proposed mechanism is restoration of glutathione peroxidase activity in the thyroid, which protects thyrocytes from peroxide damage generated during hormone synthesis. Effects are most consistent in regions with low or moderate selenium status and in patients not yet on thyroid hormone replacement.

Magnitude: Standardized mean difference for TPOAb reduction approximately -0.96; TSH reduction in untreated patients approximately -0.21 standard deviations.

Restoration of Selenoprotein Activity in Deficient Individuals

In adults with low baseline selenium (typically below 90 micrograms per liter in plasma), supplementation reliably increases activity of glutathione peroxidase and selenoprotein P toward saturation, the biochemical correlate of selenium adequacy. This effect is the basis for selenium being classified as essential and is well documented in controlled human studies and in the Linus Pauling Institute monograph.

Magnitude: Plasma GPx activity plateaus at selenium intakes of about 75-105 micrograms per day; selenoprotein P plateaus near 105-125 micrograms per day from baseline-deficient status.

Medium 🟩 🟩

Graves’ Ophthalmopathy Improvement

In adults with mild-to-moderate Graves’ ophthalmopathy (an autoimmune eye disease associated with thyroid disease), 200 micrograms per day of sodium selenite for 6 months slowed disease progression and improved quality of life in a multicenter European RCT, leading the European Thyroid Association — a professional association whose members deliver thyroid care and whose clinical and professional standing intersects with the conclusions it endorses — to include selenium in its treatment recommendations for this condition. The mechanism is thought to involve reduction of oxidative damage in retro-orbital tissue.

Magnitude: Significant improvement in Clinical Activity Score and quality-of-life measures versus placebo over 6 months in mild-to-moderate disease.

Cardiovascular Mortality Reduction in Deficient Older Adults (with Coenzyme Q10) ⚠️ Conflicted

The Swedish KiSel-10 trial in elderly adults with low baseline selenium reported a roughly 49% reduction in cardiovascular mortality over five years and persistent benefit at 12-year follow-up when 200 micrograms per day of selenium-enriched yeast was combined with 200 milligrams per day of CoQ10 (coenzyme Q10, a mitochondrial cofactor and antioxidant). Other trials in selenium-replete populations or with selenium alone have not shown comparable cardiovascular benefit, and not all subgroup analyses have been confirmed. Two large ongoing Phase 3 trials (DANUTRIO-HF and SELEQT-HF) are designed to test this combination in heart failure populations. The evidence is therefore promising but currently restricted to one principal trial and one selenium-deficient population.

Magnitude: Hazard ratio for cardiovascular mortality approximately 0.51 versus placebo over 5 years in selenium-deficient older Swedish adults co-supplemented with CoQ10.

Modest Improvement in Lipid Markers

A 2018 meta-analysis of 11 RCTs found small but statistically significant reductions in total cholesterol, triglycerides, and VLDL with selenium supplementation, without significant change in LDL or HDL. Clinical relevance is modest, and effects appear concentrated in populations with metabolic risk factors.

Magnitude: Standardized mean differences approximately -0.13 for total cholesterol, -0.19 for triglycerides, and -0.34 for VLDL.

Low 🟩

Immune Function Modulation

Across nine controlled trials, selenium supplementation produced inconsistent effects on most immune markers but reliably increased NK cell lytic activity. NK cell count followed an inverted U-shaped pattern with selenium status, suggesting the immune benefits plateau or reverse at high intake. Mechanistically, selenoproteins influence T-cell proliferation, redox balance during immune activation, and viral mutation rates.

Magnitude: Increased NK cell lytic activity reported in supplemented groups; inconsistent effects on immunoglobulin and white-cell measures across trials.

Sperm Quality Improvement

Selenium is required for the integrity of the sperm flagellum through the structural selenoprotein GPx4 (glutathione peroxidase 4, an enzyme that protects membrane lipids from peroxidation). A 26-week trial of 200 micrograms per day improved sperm concentration and motility versus placebo, with effects correlating with rising seminal-plasma selenium. Other trials, particularly in selenium-replete men, have shown smaller or no effects, so the magnitude is best described as modest and population-dependent.

Magnitude: Modest absolute improvements in sperm concentration and motility over 26 weeks at 200 micrograms per day in subfertile men.

Speculative 🟨

All-Cause Mortality and Longevity Association

Observational cohorts have repeatedly identified an inverted U-shaped association between plasma selenium and all-cause mortality, with apparent optimum near 130 micrograms per liter and higher mortality at both lower and higher levels. No RCT has tested selenium for all-cause mortality as a primary endpoint, so the evidence is associative and confounded; the basis is mechanistic and observational rather than interventional.

Cancer Prevention in Selenium-Deficient Populations ⚠️ Conflicted

Earlier observational data and the NPC trial suggested benefit on cancer endpoints in low-selenium populations, while the larger SELECT trial in selenium-replete men found no benefit and signal of harm. Subgroup analyses in NPC suggested the benefit was concentrated in men with the lowest baseline selenium. There is no confirmatory RCT in deficient populations, so this remains speculative.

Cognitive Aging Support

Cross-sectional and small longitudinal studies have associated higher selenium status with better cognitive performance and lower dementia risk, particularly in selenium-deficient regions of China. No adequately powered RCT has tested selenium for cognitive endpoints; the basis is mechanistic (oxidative stress in brain tissue) and observational.

Benefit-Modifying Factors

Baseline selenium status: The single most important modifier. Benefits cluster in adults with plasma selenium below approximately 110 micrograms per liter; replete adults rarely benefit and may be harmed by additional intake.
Genetic polymorphisms: Variants in GPX1 (glutathione peroxidase 1, the major cytosolic antioxidant selenoenzyme), SELENOP (selenoprotein P, the main selenium transport protein), and SEP15 (selenoprotein 15, an endoplasmic reticulum redox protein) alter selenoprotein activity and individual selenium needs. The Pro198Leu variant in GPX1 (a single-amino-acid substitution that reduces enzyme catalytic efficiency) has been associated with reduced enzyme response to supplementation in some studies.
Iodine status: Selenium supplementation in the context of low iodine status can aggravate hypothyroidism by accelerating clearance of thyroid hormone; iodine should be assessed before selenium is added for thyroid support.
Sex-based differences: In observational cancer data, men appear to derive more benefit at low selenium status than women. Conversely, the increase in type 2 diabetes risk seen with supplementation may be greater in women, particularly those with metabolic risk factors.
Age-related considerations: Older adults, particularly those over 70, more often have suboptimal selenium status and are the population in which combined selenium plus CoQ10 has shown cardiovascular benefit. They are also the population in which uncritical supplementation poses the highest metabolic risk, so age increases both potential benefit and need for monitoring.
Pre-existing conditions: Hashimoto thyroiditis and mild-to-moderate Graves’ ophthalmopathy are the conditions with the strongest specific evidence for benefit. Chronic kidney disease can alter selenium metabolism and may affect both efficacy and safety.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Increased Type 2 Diabetes Risk

Selenium supplementation has been associated with an increased risk of type 2 diabetes in randomized and observational data. The Vinceti et al. 2018 meta-analysis (5 RCTs) reported an 11% increase in incident type 2 diabetes (RR (relative risk, the ratio of an outcome’s probability between two groups) 1.11, 95% CI (confidence interval, the range of plausible values for the estimate) 1.01-1.22), and observational data show a clear dose-response, with up to a roughly 3.6-fold higher risk at plasma selenium of about 140 micrograms per liter compared with low-status individuals. Proposed mechanisms include selenoprotein-mediated suppression of insulin signaling and altered glucose uptake in muscle and adipose tissue. The signal is most consistent in selenium-replete populations.

Magnitude: RR 1.11 (95% CI 1.01-1.22) for type 2 diabetes in pooled RCTs; observational dose-response up to about 3.6-fold higher risk at high plasma selenium.

Selenosis (Chronic Selenium Toxicity)

Sustained intake above the tolerable upper intake level of 400 micrograms per day from all sources can produce selenosis (chronic selenium toxicity), characterized by garlic-like breath odor, brittle hair and nails, hair loss, dermatitis, fatigue, irritability, gastrointestinal disturbance, and peripheral neuropathy (nerve damage causing numbness or tingling). Severe acute toxicity from accidental overdosing has caused respiratory distress, cardiac dysfunction, and renal failure. The mechanism involves nonspecific incorporation of selenium into proteins replacing sulfur, disrupting structure and function.

Magnitude: Symptoms typically emerge above 400 micrograms per day from all sources; severe toxicity reported with intakes exceeding 1,000 micrograms per day, including a documented outbreak from a mislabeled supplement that delivered roughly 200-fold the labeled dose.

Medium 🟥 🟥

Increased High-Grade Prostate Cancer Risk in Selenium-Replete Men ⚠️ Conflicted

In SELECT, post hoc analyses suggested an increased risk of high-grade prostate cancer in men with the highest baseline selenium status who received selenium supplementation. The overall trial did not reach statistical significance for the prostate-cancer endpoint in the full population, and the NPC trial in lower-selenium men had earlier reported reduced prostate cancer incidence. The current view is that supplementation is most likely to increase risk in men whose baseline selenium is already adequate; this remains an area where the evidence is genuinely conflicted between trials.

Magnitude: Elevated incidence of high-grade prostate cancer in the highest baseline-selenium quartile of SELECT; non-significant overall RR around 1.0 in the full SELECT population.

Increased Skin Cancer Risk

The NPC trial and the Cochrane analysis observed increased non-melanoma skin cancer with selenium supplementation (RR approximately 1.16 for non-melanoma skin cancer), with similar signals for melanoma in subgroup analyses. Mechanism is unclear but may involve pro-oxidant effects at supraphysiological tissue selenium concentrations.

Magnitude: Modest absolute increase in non-melanoma skin cancer incidence in supplemented arms; effect sizes vary across analyses.

Low 🟥

Gastrointestinal Disturbance

Some adults experience nausea, abdominal discomfort, or loose stools with selenium supplementation, more commonly with inorganic forms such as sodium selenite than with selenomethionine. Symptoms are typically mild and dose-dependent, and they tend to resolve with dose reduction or change of form.

Magnitude: Reported in a minority of trial participants; rates are typically not statistically different from placebo at 100-200 micrograms per day of organic selenium.

Alopecia and Dermatitis

The SELECT trial reported a small but statistically significant increase in alopecia (hair loss) and dermatitis (skin inflammation) in the selenium arm versus placebo. These are also early features of selenosis, which may explain the signal in long-term high-dose use.

Magnitude: Statistically significant absolute increase in alopecia and dermatitis events versus placebo over the SELECT supplementation period at 200 micrograms per day.

Speculative 🟨

Pro-Oxidant Effects at Supraphysiological Doses

Selenium compounds can shift from antioxidant to pro-oxidant behavior at high tissue concentrations, generating reactive oxygen species and damaging DNA in cell-culture and animal models. Whether this contributes to the observed metabolic and oncologic risks at high human intake is plausible but not directly demonstrated; the basis is mechanistic.

Worsening of Pre-Existing Insulin Resistance

Observational analyses have linked higher plasma selenium with worsening fasting glucose and insulin trajectories in adults with pre-existing metabolic disease, though without direct interventional confirmation in this subgroup. The basis is mechanistic and observational.

Risk-Modifying Factors

Baseline selenium status: Replete or high-status individuals (plasma selenium above approximately 125 micrograms per liter) face the greatest risk of both metabolic and oncologic harms from supplementation. Status-guided dosing, rather than fixed protocols, is the central risk-modifying principle.
Genetic polymorphisms: Variants in GPX1 (glutathione peroxidase 1), SOD2 (superoxide dismutase 2, a mitochondrial antioxidant enzyme), and selenoprotein genes may influence individual susceptibility to oxidative imbalance. The Pro198Leu GPX1 variant has been linked to differential cancer and cardiovascular risk in some cohorts.
Sex-based differences: Women appear to face larger relative increases in type 2 diabetes risk from supplementation than men, particularly when baseline selenium is adequate. Prostate cancer risk is, by definition, male-specific.
Pre-existing conditions: Pre-diabetes, type 2 diabetes, and metabolic syndrome amplify metabolic risk. A history of high-grade prostate cancer or non-melanoma skin cancer raises the threshold for supplementation. Severe kidney disease may alter selenium handling.
Age-related considerations: Older adults are more susceptible to both subclinical deficiency and to metabolic complications of supplementation. Diabetes-related risk signals in subgroup analyses of NPC were more pronounced in older participants.

Key Interactions & Contraindications

Prescription drug interactions:
- Anticoagulants and antiplatelet agents (warfarin, clopidogrel, apixaban): Caution. Selenium may modestly enhance bleeding risk through antioxidant effects on platelet function; monitor INR (international normalized ratio, a measure of how long blood takes to clot) more frequently when initiating or stopping selenium.
- Eltrombopag (a thrombopoietin receptor agonist used to treat low platelet counts): Caution. Selenium may decrease absorption through cation binding; separate administration by at least 2 hours.
- Tyrosine kinase inhibitors that chelate cations (TKIs, oral targeted cancer drugs that inhibit signaling enzymes; bosutinib, dabrafenib): Caution. Mineral supplements can reduce absorption; separate dosing by 2-4 hours.
- Statins (HMG-CoA reductase inhibitors that lower LDL cholesterol; atorvastatin, rosuvastatin, simvastatin): Monitor. Selenium plus other antioxidants has been reported to blunt the HDL-raising effect of niacin-statin combinations in one cardiovascular trial; clinical impact at standard doses is uncertain.
- Levothyroxine and thyroid hormone replacement (a synthetic thyroxine medication used for hypothyroidism): Monitor. Selenium can alter thyroid hormone conversion and may shift TSH and free T4 levels; monitor thyroid panel after starting or stopping.
Over-the-counter medication interactions:
- Antacids and proton pump inhibitors (e.g., omeprazole, esomeprazole): Caution. Reduced gastric acidity may impair absorption of inorganic selenium; separate dosing by at least 2 hours.
- Cation-containing supplements (calcium, magnesium, iron): Caution. May modestly reduce selenium absorption when taken simultaneously; separate by 2 hours when feasible.
Supplement interactions:
- Vitamin E (alpha-tocopherol): Monitor. Synergistic antioxidant interaction; combined high-dose use was studied in SELECT without clear benefit and potentially with harm in selenium-replete men.
- Zinc: Caution. High-dose zinc may interfere with selenoprotein synthesis and selenium absorption; keep total zinc below 40 milligrams per day when co-supplementing.
- Iodine (potassium iodide, kelp): Caution. Selenium without adequate iodine can worsen hypothyroidism; address iodine first when supplementing for thyroid.
- Coenzyme Q10: Monitor. Potentially synergistic for cardiovascular outcomes in selenium-deficient older adults (KiSel-10), though not for replete populations.
- High-dose vitamin C (above 1,000 milligrams per day): Monitor. May reduce bioavailability of inorganic selenium when taken together; separate dosing by 2 hours.
Other intervention interactions: Discontinue selenium at least 2 weeks before elective surgery to limit any potential effect on bleeding risk.
Additive effects: Combined use with other antioxidant supplements (vitamin E, vitamin C, beta-carotene) may produce additive antioxidant exposure; in the SELECT and ATBC trials, combined antioxidant supplementation in replete populations did not reduce cancer risk and in some analyses increased it.
Populations who should avoid supplementation (without specific medical supervision):
- Adults with plasma selenium above 125 micrograms per liter.
- Adults with type 2 diabetes, pre-diabetes (HbA1c (glycated hemoglobin, a marker of average blood glucose over 2-3 months) 5.7-6.4%), or metabolic syndrome who are not selenium-deficient.
- Men with a history of high-grade prostate cancer (Gleason score 7 or higher) or strong family risk who already have adequate selenium status.
- Adults with a history of non-melanoma skin cancer or melanoma.
- Individuals with stage 4-5 chronic kidney disease (eGFR (estimated glomerular filtration rate, a measure of kidney function) below 30 mL/min/1.73 m²).
- Pregnant or breastfeeding adults outside dietary intake levels.

Risk Mitigation Strategies

Baseline selenium testing before supplementing: Measure plasma or serum selenium and supplement only when baseline is below approximately 110 micrograms per liter, mitigating the type 2 diabetes and prostate cancer risks that are concentrated in replete individuals.
Cap total intake at 200 micrograms per day from supplements: Hold supplemental selenium at no more than 200 micrograms per day, accounting for the 100-120 micrograms typically supplied by a Western mixed diet, to keep total intake well below the 400 microgram per day tolerable upper intake level and reduce the risk of selenosis.
Prefer organic selenium forms: Use selenomethionine or selenium-enriched yeast over sodium selenite to reduce gastrointestinal side effects and to provide more predictable kinetics; this also reduces the risk of selenosis at any given supplemental dose.
Periodic metabolic monitoring: Check fasting glucose and HbA1c at baseline and every 6 months during supplementation to detect emerging type 2 diabetes risk early.
Periodic selenium monitoring: Re-measure plasma selenium 2-3 months after initiation and every 6-12 months thereafter, targeting 110-130 micrograms per liter and reducing or stopping supplementation if levels exceed approximately 140 micrograms per liter.
Iodine and thyroid panel before thyroid-focused use: Confirm adequate iodine intake and obtain a baseline thyroid panel (TSH, free T4) before starting selenium for thyroid autoimmunity, mitigating the risk of worsening hypothyroidism.
Avoid stacking with high-dose Brazil nuts: Limit Brazil nut intake to occasional rather than daily consumption when supplementing, since one to two Brazil nuts can supply 70-180 micrograms of selenium and unpredictably push total intake into the harmful range.
Surveillance for early selenosis signs: Monitor for garlic-like breath, hair shedding, brittle nails, and unexplained fatigue at each follow-up; these are early markers of excess that warrant immediate dose reduction.

Therapeutic Protocol

A standard protocol for selenium reflects both the dosing used in major thyroid and cancer trials and the cautious adjustments that have emerged as the type 2 diabetes signal has been replicated.

Standard dose for thyroid autoimmunity: 200 micrograms per day of selenomethionine or selenium-enriched yeast, used in the majority of Hashimoto and Graves’ ophthalmopathy trials. The European Thyroid Association — a professional association whose membership has direct clinical interest in the conclusions it endorses — recommends 200 micrograms per day of sodium selenite for 6 months in mild-to-moderate Graves’ ophthalmopathy.
Conservative dose for general status correction: 100 micrograms per day for adults whose baseline selenium is in the lower half of the reference range or who already take a multivitamin containing 25-55 micrograms.
Upper limit: Total intake from all sources (diet and supplements) should remain under 400 micrograms per day, the established tolerable upper intake level.
Competing therapeutic approaches: Two principal approaches coexist. One approach, articulated by much of academic endocrinology, minimizes selenium supplementation outside specific clinical indications and treats Hashimoto thyroiditis primarily with thyroid hormone replacement, citing the SELECT trial as evidence against population-level supplementation. A second approach, articulated by clinicians such as Chris Kresser and by Life Extension, uses selenium supplementation more readily, particularly for thyroid autoimmunity, sometimes in mixed-form preparations of selenomethionine, sodium selenite, and methylselenocysteine, alongside baseline status testing. Both approaches sit on competing readings of the same RCT and observational evidence.
Best time of day: Selenium can be taken at any time of day. Taking it with a meal containing some fat improves tolerability, particularly with sodium selenite, and supports absorption.
Half-life: Selenium does not have a single classical half-life; selenomethionine is incorporated nonspecifically into body proteins at methionine positions and is retained for weeks to months, while inorganic sodium selenite is more rapidly excreted in urine. Whole-body selenium turnover is on the order of months in steady state.
Single dose vs. split dose: A single daily dose is standard and matches the dosing used in nearly all major trials. There is no demonstrated advantage to splitting doses.
Genetic considerations: Variants in GPX1, SELENOP, and SEP15 may modify response, and the Pro198Leu GPX1 variant has been associated with reduced enzyme response in some studies; pharmacogenomic testing is not yet standard but may inform personalized dosing as research matures.
Sex-based differences in protocol: Women, particularly those with metabolic risk factors, may reasonably prefer the lower 100-150 micrograms per day end of the range given the larger relative risk of type 2 diabetes signal in women.
Age-related considerations: Older adults (above 65) more often have suboptimal status and may benefit most, but warrant tighter metabolic monitoring than younger adults; status-guided dosing is preferred over routine supplementation.
Baseline biomarkers: Decision to supplement is best guided by plasma selenium. Adults below 85 micrograms per liter are most likely to benefit; 85-110 micrograms per liter may benefit modestly; 110-125 micrograms per liter generally do not need supplementation; above 125 micrograms per liter, supplementation is generally not advised.
Pre-existing conditions: Hashimoto thyroiditis: 200 micrograms per day of selenomethionine for at least 6 months, with TPOAb and TSH monitoring. Mild-to-moderate Graves’ ophthalmopathy: 200 micrograms per day of sodium selenite for 6 months per European Thyroid Association guidance. Pre-diabetes or type 2 diabetes: avoid unless clearly deficient and monitor metabolic markers closely if used.

Discontinuation & Cycling

Lifelong vs. short-term use: Selenium is typically taken indefinitely as a status-corrective intervention, with periodic reassessment of plasma selenium and metabolic markers, rather than for a fixed duration. For specific conditions such as Graves’ ophthalmopathy, a defined 6-month course is the protocol used in trials. Once status reaches 110-130 micrograms per liter, dose reduction or discontinuation is reasonable.
Withdrawal effects: There are no documented acute withdrawal effects from stopping selenium. Selenoprotein activity declines gradually over weeks to months as tissue stores are depleted, after which thyroid antibodies and antioxidant capacity may drift toward pre-supplementation values.
Tapering protocol: A formal tapering protocol is not required; selenium can be discontinued without dose reduction.
Cycling: Routine cycling is not established in the literature. Some practitioners use periodic 1-2 month “supplement holidays” to reassess baseline status, but the rationale is monitoring, not preservation of efficacy.

Sourcing and Quality

Preferred forms: Selenomethionine and selenium-enriched yeast are well-absorbed (typically above 90%) and were the forms used in most major trials, including NPC and KiSel-10. Sodium selenite is the form used in the European Graves’ ophthalmopathy trial and remains an inexpensive, well-studied option. Methylselenocysteine is a third form, with mechanistic data in cancer biology but less clinical-trial support. Some experts argue for mixed-form products for broader biological coverage.
Third-party testing: Look for products independently tested by USP, NSF International, or ConsumerLab. ConsumerLab testing has reported wide variability in actual selenium content versus label.
Purity considerations: Selenium yeast products should disclose the proportion of organic versus inorganic selenium. Heavy metal contamination (lead, cadmium, arsenic) is a concern in some mineral supplements; certificates of analysis are useful.
Reputable brands: Brands frequently identified in independent testing and clinical use include Life Extension Super Selenium Complex (mixed-form), Thorne Selenomethionine, Pure Encapsulations Selenium, and NOW Foods Selenium.
Food sources: Brazil nuts contain 70-180 micrograms of selenium per nut, with high variability by region. Yellowfin tuna, halibut, sardines, eggs, beef liver, turkey, and chicken are reliable food sources. Brazil nuts are an efficient way to raise status but their high selenium variability and high omega-6 linoleic acid content make them poorly suited as a precise daily source.

Practical Considerations

Time to effect: Plasma selenium typically rises within 2-4 weeks of starting supplementation. Glutathione peroxidase activity reaches plateau over 6-12 weeks. Thyroid antibody reductions in Hashimoto thyroiditis are typically observed over 3-6 months.
Common pitfalls:
- Supplementing without baseline plasma selenium testing, which risks driving replete individuals into the harmful range.
- Combining a daily Brazil nut habit with a selenium supplement, occasionally producing intakes above 400 micrograms per day.
- Adding selenium for thyroid health without correcting iodine status first.
- Using older 1990s cancer-prevention dosing rationales in selenium-replete populations.
- Failing to monitor fasting glucose and HbA1c during long-term supplementation, missing the metabolic risk signal.
Regulatory status: Selenium is sold over the counter as a dietary supplement in the United States and most jurisdictions and is regulated by the FDA under DSHEA (Dietary Supplement Health and Education Act, the U.S. law governing dietary supplements). The U.S. RDA (recommended dietary allowance, the daily intake adequate for nearly all healthy adults) is 55 micrograms; the tolerable upper intake level is 400 micrograms.
Cost and accessibility: Selenium is inexpensive and widely available. ConsumerLab has reported per-dose costs ranging from a few cents to over a dollar for tested products; most generic selenomethionine bottles cost under 15 USD per 3-month supply.

Interaction with Foundational Habits

Sleep: Direct interaction with sleep is essentially absent. Indirectly, optimal thyroid hormone conversion supported by adequate selenium status may stabilize circadian and metabolic regulation, but no controlled studies show selenium altering sleep architecture. There is no evidence of stimulant effects, and timing relative to bedtime is not a practical concern.
Nutrition: Direct, two-way interaction. Diet supplies the bulk of selenium intake (typically 100-120 micrograms per day in most North American diets, less in much of Europe and parts of Asia). Adequate methionine supply supports incorporation of selenomethionine; adequate iodine supports the thyroid pathway in which selenoenzymes operate. Combined intake from food and supplements should be monitored to avoid exceeding 400 micrograms per day; named studies such as NPC and SELECT specifically used 200 micrograms per day on top of background dietary intake.
Exercise: Indirect, modest. Intense or prolonged exercise increases oxidative stress, which selenoenzymes help neutralize, but RCTs have not demonstrated that selenium supplementation enhances performance, recovery, or hypertrophy in selenium-replete individuals. Selenium does not appear to blunt exercise-induced adaptations, and timing relative to workouts is not a practical concern at typical doses.
Stress management: Indirect. Antioxidant selenoenzymes contribute to managing oxidative stress associated with chronic psychological stress, and observational data link low selenium status to higher rates of depression and anxiety. Direct effects on cortisol or HPA axis (hypothalamic-pituitary-adrenal axis, the body’s central stress-response system) function have not been established in controlled human studies, so any effect on subjective stress is best treated as indirect.

Monitoring Protocol & Defining Success

Baseline testing is performed before supplementation to confirm that selenium is needed and to establish reference values for thyroid, glucose, and lipid metabolism that selenium can plausibly affect.

Ongoing monitoring is performed at 2-3 months after initiation, then every 6-12 months thereafter, with closer follow-up if a metabolic or thyroid endpoint is being tracked.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Plasma or serum selenium	110-130 mcg/L	Determines need for supplementation and detects excess	Conventional reference range typically 70-150 mcg/L; fasting not required; low albumin or active inflammation (high CRP) reduces reliability. CRP (C-reactive protein) is a general marker of systemic inflammation.
Glutathione peroxidase activity	Above plateau for assay used	Functional readout of selenoprotein status	Optional; useful when plasma selenium is borderline; assay-dependent
TSH	0.5-2.5 mIU/L	Baseline thyroid function, especially before thyroid-focused use	Conventional range 0.4-4.0 mIU/L; best measured in early morning
Free T4	1.0-1.5 ng/dL	Assess thyroid hormone production	Conventional range 0.8-1.8 ng/dL
TPOAb	< 35 IU/mL	Screen for thyroid autoimmunity and track response	Relevant when supplementing for thyroid; meaningful changes typically take 3-6 months
Fasting glucose	75-90 mg/dL	Baseline and ongoing metabolic risk	Conventional range 70-100 mg/dL; rising values warrant dose reduction
HbA1c	4.8-5.3%	Long-term glycemic trajectory	Conventional cutoff < 5.7% normal; monitor due to type 2 diabetes risk signal
Fasting insulin	2-6 mIU/L	Detects early insulin resistance	Conventional range 2.6-24.9 mIU/L; pair with fasting glucose for HOMA-IR (homeostatic model assessment of insulin resistance, a calculated marker of insulin sensitivity)
Lipid panel (TC, LDL, HDL, TG)	Per individual targets	Track modest expected lipid changes	Conventional fasting lipid panel; minor reductions in TC, TG, VLDL possible

Qualitative markers of success include:

Stable or improving energy and cognitive clarity.
Absence of selenosis indicators (garlic-like breath, hair shedding, brittle nails).
For thyroid autoimmunity, gradual reduction in TPOAb and stabilization of TSH.
Maintained antioxidant status without rising fasting glucose or HbA1c.

The biomarker table above already indicates relevant fasting and timing considerations in the Context/Notes column.

Emerging Research

DANUTRIO-HF heart failure trial: A Danish pragmatic Phase 3 RCT enrolling approximately 4,044 heart failure adults randomized to selenium (100 micrograms twice daily), CoQ10 (100 milligrams twice daily), the combination, or placebo, with cardiovascular mortality as a key endpoint. Registered as NCT06694727. This is the largest direct test of the KiSel-10 hypothesis in heart failure to date.
SELEQT-HF replication trial: A Dutch Phase 3 RCT enrolling approximately 1,100 heart failure patients to test selenium plus CoQ10 versus placebo, providing an independent replication of the same question. Registered as NCT07234422.
Selenium in moderately-to-severely active ulcerative colitis: A Phase 2 proof-of-concept RCT in 180 adults with active ulcerative colitis, evaluating whether selenium improves response to biologic and small-molecule therapies. Registered as NCT07427017.
Selenium and pediatric depression: A Phase 2 RCT enrolling about 172 children and adolescents to test selenium for depression. Registered as NCT07203144.
Form-specific effects (selenomethionine vs methylselenocysteine vs selenite): Active area of research suggesting that different selenium chemistries may have distinct anti-cancer, immune, and metabolic activities beyond simple selenium delivery. Relevant published evidence includes the umbrella review Selenium intake and multiple health-related outcomes: an umbrella review of meta-analyses by Wang et al., 2023, which integrated meta-analyses across diverse outcomes and confirmed the U-shaped status-outcome relationship.
Selenium and metabolic disease mechanisms: Mechanistic and biomarker studies of selenoprotein P and selenium status are progressing, including Selenium status and its determinants in very old adults: insights from the Newcastle 85+ Study by Perri et al., 2023, which could refine future risk stratification for who should and should not supplement.
Selenium and infectious disease outcomes: Selenium status has been linked to severity of viral infections in observational data. Trials of selenium in respiratory infections, including post-COVID rehabilitation, are ongoing and may further define the immune-modulating role described in Filippini et al., 2023.
Negative or risk-relevant directions: Long-term follow-ups of SELECT and NPC continue to clarify cancer and metabolic outcomes; these analyses are designed to detect both delayed harms (such as type 2 diabetes incidence over decades) and any persistent benefits in baseline-deficient subgroups.

Conclusion

Selenium is an essential trace mineral with clearly defined biochemistry and a narrow therapeutic window. Its strongest claim to a place in a longevity-oriented protocol comes from thyroid autoimmunity, where pooled trial evidence reports reductions in thyroid antibodies and modest improvements in thyroid signaling, and from the correction of measurable deficiency, where supplementation restores selenoprotein activity. Mild-to-moderate Graves’ ophthalmopathy adds a defined indication, endorsed by the European Thyroid Association, whose membership has clinical ties to thyroid care that intersect with the conclusions it endorses.

Outside these settings, status-blind supplementation in adults whose selenium is already adequate carries a clearer harm signal than benefit signal in the available data: a reported increase in type 2 diabetes risk, with observational data suggesting larger differences at higher plasma selenium. The earlier hypothesis of broad cancer prevention has not been borne out in large randomized evidence, and one large trial reported increased high-grade prostate cancer and skin cancer signals in already-replete men. The combination of selenium with coenzyme Q10 in older adults with low status produced a notable cardiovascular signal in one principal trial.

The evidence base is uneven across endpoints, with meta-analytic support in thyroid autoimmunity, mixed and conflicted findings in cancer, and a single major positive signal in cardiovascular mortality. One framing read of this evidence holds that benefit and risk track baseline selenium status more than dose; competing readings emphasize chemical form, trial duration, or population heterogeneity, and the question is not settled.

Top - Benefits - Risks - Protocol

Selenium for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Thyroid Autoimmunity Support

Restoration of Selenoprotein Activity in Deficient Individuals

Medium 🟩 🟩

Graves’ Ophthalmopathy Improvement

Cardiovascular Mortality Reduction in Deficient Older Adults (with Coenzyme Q10) ⚠️ Conflicted

Modest Improvement in Lipid Markers

Low 🟩

Immune Function Modulation

Sperm Quality Improvement

Speculative 🟨

All-Cause Mortality and Longevity Association

Cancer Prevention in Selenium-Deficient Populations ⚠️ Conflicted

Cognitive Aging Support

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Increased Type 2 Diabetes Risk

Selenosis (Chronic Selenium Toxicity)

Medium 🟥 🟥

Increased High-Grade Prostate Cancer Risk in Selenium-Replete Men ⚠️ Conflicted

Increased Skin Cancer Risk

Low 🟥

Gastrointestinal Disturbance

Alopecia and Dermatitis

Speculative 🟨

Pro-Oxidant Effects at Supraphysiological Doses

Worsening of Pre-Existing Insulin Resistance

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion